MAPT and Alzheimer disease: Some studies showed that AD patients had increased clusterin levels due to neurodegeneration, which could significantly ameliorate tau pathology by inhibiting fibril formation (Nuutinen et al. 2009; Schrijvers et al. 2011; Cunin et al. 2016).